A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Trial Profile

A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs FX 322 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Therapeutic Use
  • Sponsors Frequency Therapeutics
  • Most Recent Events

    • 08 Aug 2018 Status changed from planning to recruiting.
    • 22 Feb 2018 New trial record
    • 15 Feb 2018 According to a Frequency Therapeutics media release, this trial is anticipated to begin in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top